GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals, Vaccines, Consumer Healthcare, and Corporate Executive Team (CET). The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The CET segment refers to the management of business activities. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Company profile
Ticker
GSK
Exchange
Website
CEO
Emma Walmsley
Employees
Incorporated
Location
Industry (SIC)
Former names
GLAXOSMITHKLINE PLC
SEC CIK
GSK stock data
News

GlaxoSmithKline: Dividend Insights
16 May 22
HC Wainwright Says This Stock Is Well Capitalized For Value Realization Of Pipeline, Despite COVID-19 Uncertainty
12 May 22
GSK's Panadol and Sensodyne-maker Haleon in Talks to Hire Banks
3 May 22
GlaxoSmithKline Clocks 32% Topline Growth Buoyed By COVID-19 Therapy, Shingrix Vaccine
27 Apr 22
GlaxoSmithKline Earlier Reported Q1 EPS $0.88 Beats $0.76 Estimate, Sales $13.13B Beat $11.70B Estimate
27 Apr 22
Press releases
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
5 May 22
Voltaren Teams Up with Actress Jennie Garth to Support Caregivers Nationwide
4 May 22
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
2 May 22
MOBI Makes Their Post-Pandemic NYC Debut
2 May 22
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
25 Apr 22
Calendar
8 Mar 22
20 May 22
Financial summary
Quarter (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Jul 21 | GSK | Common Stock | Buy | Acquire P | Yes | No | 18 | 275,000 | 4.95M | 1,007,583 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 635,646 | 0 | 732,583 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 27,345 | 0 | 96,937 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 8,380 | 0 | 69,592 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 14,917 | 0 | 61,212 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 12,979 | 0 | 46,295 |
2 Jul 21 | GSK | Common Stock | Conversion | Acquire C | Yes | No | 0 | 1,505 | 0 | 33,316 |
2 Jul 21 | GSK | Series G Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 10,055,408 | 0 | 0 |
2 Jul 21 | GSK | Series F-2 Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 1,081,434 | 0 | 0 |
2 Jul 21 | GSK | Series E-2 Preferred Stock Common Stock | Conversion | Dispose C | Yes | No | 0 | 331,399 | 0 | 0 |
Institutional ownership, Q1 2022
13.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 884 |
Opened positions | 104 |
Closed positions | 110 |
Increased positions | 331 |
Reduced positions | 258 |
13F shares | Current |
---|---|
Total value | 14.37B |
Total shares | 330.32M |
Total puts | 3.95M |
Total calls | 4.88M |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Dodge & Cox | 85.75M | $3.74B |
Capital International Investors | 19.1M | $832.01M |
Fisher Asset Management | 18.97M | $826.21M |
FMR | 16.92M | $736.84M |
TROW T. Rowe Price | 15.19M | $661.56M |
Renaissance Technologies | 10.01M | $436.12M |
Arrowstreet Capital, Limited Partnership | 9.62M | $419.11M |
Black Creek Investment Management | 9.21M | $401.13M |
JTC Employer Solutions Trusteee | 9.02M | $392.74M |
STT State Street | 8.99M | $397.4M |
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accessible, adjuvant, Africa, ambition, andXevudy, Anne, antibody, antisense, August, Beal, bepirovirsen, bictegravir, Biktarvy, box, cabotegravir, cabozantinib, Canadian, cancer, categorisation, cephalosporin, CH, characterised, circa, circulation, clarity, cohort, CombinedTivicay, component, COVID, depemokimab, Device, Diagnostic, Dietz, difficult, digitalisation, disappointing, disciplined, distancing, distrust, dosing, drag, drove, Endorsement, engineering, exceeding, exemplar, FluLaval, freight, fuelling, fulfilment, geopolitical, Gilead, GLT, guided, Haleon, halving, HBV, headroom, hemisphere, hesitancy, highlighted, ID, immunology, inBlenrep, includingNucala, includingSeretide, inDovato, Ineffective, inflationary, inFluarix, infringement, Ingredient, inhaled, injectable, internationally, invalidating, invasion, labour, lethality, licence, lowerShingrix, maximising, meaningfully, misinformation, monetise, monoclonal, mRNA, ofArnuity, ofXevudy, oligonucleotide, omnichannel, onset, ovarian, payout, percent, perception, pharma, PIPL, pivotal, plastic, predict, preparatory, preserve, primarilyShingrix, quantify, rare, raw, rebound, rebounded, regimensJuluca, Rejection, reliant, render, retaliatory, risky, RSV, run, Russia, Ryan, slightly, Smoker, southern, sovereignty, Spain, stable, staffing, suppressed, susceptible, synthetic, temporary, theTivicay, tolerance, toXyzal, track, treatmentsand, tubing, Ukraine, underperform, unprecedented, unrepeated, unsolicited, Vitro, whereTrelegy, White, wholly, withBenlysta, Xevudy
Removed:
acceptable, accomplish, Advair, Brexit, build, candidate, capable, Cervarix, CET, collected, contaminated, content, core, cyclical, declined, deed, demerge, desired, detrimental, disaster, discounting, discourse, dramatic, emergency, evolve, execute, exit, experienced, favorable, flat, footprint, franchise, functional, impede, impeded, influenza, initiate, innate, interpreted, Judy, lawfully, leverage, Lewent, license, lose, manufacturer, marketplace, mitigation, notable, organisation, packaging, play, preferred, prevented, produce, progression, proprietary, reaching, realized, recapitalization, reimbursed, remediate, retrieval, Rotarix, selected, sharing, storage, suspension, Synflorix, Tabular, terrorism, traded, unreasonable, unrest, weaker
Financial reports
Current reports
6-K
Iain Mackay - External Appointment
19 May 22
6-K
Change of Name to GSK PLC
16 May 22
6-K
Director/pdmr Shareholding
13 May 22
6-K
Director/pdmr Shareholding
12 May 22
6-K
Block Listing Interim Review
11 May 22
6-K
Director/pdmr Shareholding
9 May 22
6-K
Result of Agm
4 May 22
6-K
Directorate Change
4 May 22
6-K
Total Voting Rights
3 May 22
6-K
1ST Quarter Results
27 Apr 22
Registration and prospectus
424B3
Prospectus supplement
17 May 22
424B3
Prospectus supplement
17 May 22
25-NSE
Exchange delisting
9 May 22
F-6EF
Automatic registration for ADRs (foreign)
6 May 22
25-NSE
Exchange delisting
2 May 22
25-NSE
Exchange delisting
14 May 21
F-3ASR
Automatic shelf registration (foreign)
26 Mar 21
F-6 POS
Automatic registration for ADRs (post-effective amendment, foreign)
15 Mar 21
25-NSE
Exchange delisting
13 Oct 20
8-A12B
Registration of securities on exchange
1 Oct 20
Other
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
8 Mar 22
UPLOAD
Letter from SEC
7 Sep 21
CORRESP
Correspondence with SEC
30 Aug 21
UPLOAD
Letter from SEC
17 Aug 21
SD
Conflict minerals disclosure
27 May 21
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
12 Mar 21
CERT
Certification of approval for exchange listing
7 Oct 20
SD
Conflict minerals disclosure
29 May 20
IRAN
Disclosure regarding Iran Threat Reduction and Syria Human Rights Act
6 Mar 20
EFFECT
Notice of effectiveness
30 Jul 19
Ownership
SC 13D/A
Nkarta / GLAXOSMITHKLINE ownership change
13 May 22
SC 13G
GLAXOSMITHKLINE / DODGE & COX ownership change
14 Feb 22
SC 13G/A
GENOCEA BIOSCIENCES / GLAXOSMITHKLINE ownership change
10 Feb 22
SC 13G
Lyell Immunopharma / GLAXOSMITHKLINE ownership change
10 Feb 22
SC 13G/A
F-star Therapeutics / GLAXOSMITHKLINE ownership change
10 Feb 22
SC 13D/A
Theravance Biopharma / GLAXOSMITHKLINE ownership change
10 Feb 22
SC 13G/A
Vir Biotechnology / GLAXOSMITHKLINE ownership change
10 Feb 22
SC 13G/A
GLAXOSMITHKLINE / BlackRock ownership change
7 Feb 22
SC 13G/A
Fulcrum Therapeutics / GLAXOSMITHKLINE ownership change
27 Sep 21
SC 13D/A
Spero Therapeutics / GLAXOSMITHKLINE ownership change
16 Sep 21
Reddit threads
I'm new to dividends and have been popping in and out for about a month, want to get serious starting June. What have I done wrong in my first draft? What would you replace? What just doesn't seem to make sense?
19 May 22
Daily Discussion Thread - May 19th, 2022
19 May 22
Daily Discussion Thread - May 18th, 2022
18 May 22
Daily Discussion Thread - May 17th, 2022
17 May 22
Daily Discussion Thread - May 16th, 2022
16 May 22
Down but not out
15 May 22
Do non-penny stocks that drop into penny stock status ever climb back to or exceed their previous ATH?
10 May 22
Dividend+Growth Stocks
8 May 22
Bring it, Fed.
5 May 22
What seems like good buys for somewhat longer term?
3 May 22